New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90

Journal of Medicinal Chemistry

Volumn 50, Issue 24, 2007, Pages 6189-6200

  Le Bras, Gaëlle ^a   Radanyi, Christine ^a   Peyrat, Jean François ^a   Brion, Jean Daniel ^a   Alami, Mouâd ^a   Marsaud, Véronique ^a   Stella, Barbara ^a   Renoir, Jack Michel ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCOUMARIN DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 7; CASPASE 8; CYCLIN DEPENDENT KINASE 4; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOVOBIOCIN; NOVOBIOCIN DERIVATIVE; PROTEIN P18; PROTEIN P43; RAF PROTEIN; TANESPIMYCIN; TOLUENE 4 SULFONIC ACID 3 [(2,2 DIMETHYLCHROMAN 6 CARBONYL)AMINO] 4 HYDRPXY 8 METHYL 2 OXO 2H CHROMEN 7 YL ESTER; TOLUENE 4 SULFONIC ACID 3 [(2,2 DIMETHYLCHROMAN 6 CARBONYL)AMINO] 7 HYDROXY 8 METHYL 2 OXO 2H CHROMEN 4 YL ESTER; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; METASTASIS; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NOVOBIOCIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC;

EID: 37849037720     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0707774     Document Type: Article

References (58)

1. (a) Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood, NJ, U.S.) 2003, 228, 111-133.
2. (b) Isaacs, J. S.; Xu, W.; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213-217.
3. (a) Richter, K.; Buchner, J. Hsp90: Chaperoning signal transduction. J. Cell. Physiol. 2001, 188, 281-290.
4. (b) Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
5. (c) Neckers, L.; Ivy, S. P. Heat shock protein 90. Curr. Opin. Oncol. 2003, 15, 419-424.
6. (d) Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82, 488-499.
7. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
8. (a) Janin, Y. L. Heat shock protein 90 inhibitors: a text book example of medicinal chemistry? J. Med. Chem. 2005, 48, 7503-7512.
9. (b) Chiosis, G.; Rodina, A.; Moulick, K. Emerging Hsp90 inhibitors: From discovery to clinic. Anticancer Agents Med. Chem. 2006, 6, 1-8.
10. (c) He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R. M.; Gewirth, D. T.; Chiosis, G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 381-390.
11. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
12. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92, 242-248.
13. (a) Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
14. (b) Schulte, T. W.; Akinaga, S.; Murakata, T.; Agatsuma, T.; Sugimoto, S.; Nakano, H.; Lee, Y. S.; Simen, B. B.; Argon, Y.; Felts, S.; Toft, D. O.; Neckers, L. M.; Sharma, S. V. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol. Endocrinol. 1999, 13, 1435-1448.
15. (c) Blagosklonny, M. V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 2002, 16, 455-462.
16. (a) Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 2005, 127, 12778-12779.
17. (b) Budison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J. Am. Chem. Soc. 2006, 128, 15529-15536.
18. (a) Galigniana, M. D.; Radanyi, C.; Renoir, J. M.; Housley, P. R.; Pratt, W. B. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J. Biol. Chem. 2001, 276, 14884-14889.
19. (b) Gougelet, A.; Bouclier, C.; Marsaud, V.; Maillard, S.; Mueller, S. O.; Korach, K. S.; Renoir, J. M. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90-and immunophilin-ligands in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 94, 71-81.
20. (a) Hinman, J. W.; Caron, E. L.; Hoeksema, H. The structure of novobiocin. J. Am. Chem. Soc. 1957, 79, 3789-3800.
21. (b) Spencer, C. F.; Rodin, J. O.; Walton, E.; Holly, F. W.; Folkers, K. Novobiocin. VII. Synthesis of novobiocic acid, dihydronovobiocic acid and cyclonovobiocic acid. J. Am. Chem. Soc. 1958, 80, 140-143.
22. (a) Wu, J.; Wang, L.; Fathi, R.; Yang, Z. Palladium-catalyzed cross-coupling reactions of 4-tosylcoumarin and arylboronic acids: synthesis of 4-arylcoumarin compounds. Tetrahedron Lett. 2002, 43, 4395-4397.
23. (b) Boland, G. M.; Donnelly, D. M. X.; Finet, J. P.; Rea, M. D. Synthesis of neoflavones by Suzuki arylation of 4-substituted coumarins. J. Chem. Soc., Perkin Trans. 1 1996, 2591-2597.
24. (a) Fringuelli, F.; Piermatti, O.; Pizzo, F. One-pot synthesis of 3-carboxycoumarins via consecutive Knoevenagel and Pinner reactions in water. Synthesis 2003, 2331-2334.
25. (b) Bonsignore, L.; Cottiglia, F.; Maccioni, A. M.; Secci, D.; Lavagna, S. M. Synthesis of coumarin-3-O-acylisoureas by dicyclohexylcarbodiimide. J. Heterocycl. Chem. 1995, 32, 573-577.
26. Bansal, V.; Kanodia, S.; Thapliyal, P. C.; Khanna, R. N. Microwave induced selective bromination of 1,4-quinones and coumarins. Synth. Commun., 1996, 26, 887-892.
27. (a) Schiedel, M. S.; Briehn, C. A.; Bäuerle, P. C-C cross-coupling reactions for the combinatorial synthesis of novel organic materials. J. Organomet. Chem. 2002, 653, 200-208.
28. (b) Schiedel, M. S.; Briehn, C. A.; Bäuerle, P. Single compound libraries of organic materials: Parallel synthesis and screening of fluorescent dyes. Angew. Chem., Int. Ed. Engl. 2001, 40, 4677-4680.
29. (a) Olivi, N.; Thomas, E.; Peyrat, J.-F.; Alami, M.; Brion, J.-D. Highly efficient p-toluenesulfonic acid-catalyzed alcohol addition or hydration of unsymmetrical arylalkynes. Synlett 2004, 2175-2179.
30. (b) Le, Bras, G.; Provot, O.; Peyrat, J.-F.; Alami, M.; Brion, J.-D. Rapid microwave assisted hydration of internal arylalkynes in the presence of PTSA: an efficient regioselective access to carbonyl compounds. Tetrahedron Lett. 2006, 47, 5497-5501.
31. (a) Hostein, I.; Robertson, D.; DiStefano, F.; Workman, P.; Clarke, P. A. Inhibition of signal transduction by the hsp90 inhibitor 17-Allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 2001, 61, 4003-4009.
32. (b) Münster, P. N.; Basso, A.; Solit, D.; Norton, L.; Rosen, N. Modulation of hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. 2001, 7, 2228-2236.
33. (c) Solit, D. B.; Zheng, F. F.; Drobnjak, M.; Münster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D. B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8, 986-993.
34. (d) Rodina, A.; Vilenchik, M.; Moulick, K.; Aguirre, J.; Kim, J.; Chiang, A.; Litz, J.; Clement, C. C.; Kang, Y.; She, Y.; Wu, N.; Felts, S.; Wipf, P.; Massague, J.; Jiang, X.; Brodsky, J. L.; Krystal, G. W.; Chiosis, G. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat. Chem. Biol. 2007, 3, 498-507.
35. (a) Burrows, F.; Zhang, H.; Kamal, A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004, 12, 1530-1536.
36. (b) Pearl, L. H.; Prodromou, C. Structure and mechanism of the hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271-294.
37. (a) Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
38. (b) Ali, M. M. U.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440, 1013-1017.
39. (c) Vaughan, C. K.; Gohlke, U.; Sobott, F.; Good, V. M.; Ali, M. M. U.; Prodromou, C.; Robinson, C. V.; Saibil, H. R.; Pearl, L. H. Structure of an hsp90-cdc37-cdk4 complex. Mol. Cell 2006, 23, 697-707.
40. (a) Söti, C.; Ràcz, A.; Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of hsp90. J. Biol. Chem. 2002, 277, 7066-7075.
41. (b) Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of hsp90. Evidence that coumarin antibiotics disrupt hsp90 dimerization. J. Biol. Chem. 2006, 281, 7161-7171.
42. Marsaud, V.; Gougelet, A.; Maillard, S.; Renoir, J. M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 2003, 17, 2013-2027.
43. c-erbB_2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 1996, 271, 22796-22801.
44. (b) Münster, P. N.; Marchion, D. C.; Basso, A. D.; Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT dependent pathway. Cancer Res. 2002, 62, 3132-3137.
45. Marx, C.; Yau, C.; Banwait, S.; Zhou, Y.; Scott, G. K.; Hann, B.; Park, J. W.; Benz, C. C. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol. Pharmacol. 2007, 71, 1525-1534.
46. Caplan, A. J.; Mandal, A. K.; Theodoraki, M. A. Molecular chaperones and protein kinase quality control. Trends Cell Biol. 2007, 17, 87-92.
47. Stepanova, L.; Leng, X.; Parker, S. B.; Harper, J. W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 1996, 10, 1491-1502.
48. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M., Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
49. Wellbrock, C.; Karasarides, M.; Marais, R. The Raf proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5, 875-885.
50. Nicholson, R. I.; Hutcheson, I. R.; Hiscox, S. E.; Knowlden, J. M.; Giles, M.; Barrow, D.; Gee, J. M. W. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr. Relat. Cancer 2005, 12, S29-S36.
51. Bratton, S. B.; MacFarlane, M.; Cain, K.; Cohen, G. M. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell Res. 2000, 256, 27-33.
52. Jänicke, R. U.; Sprengart, M. L.; Wati, M. R.; Porter, A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 1998, 273, 9357-9360.
53. Liang, Y.; Yan, C.; Schor, N. F. Apoptosis in the absence of caspase 3. Oncogene 2001, 20, 6570-6578.
54. Germain, M.; Affar, E. B.; D', Amours, D.; Dixit, V. M.; Salvesen, G. S.; Poirier, G. G. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. J. Biol. Chem. 1999, 274, 28379-28384.
55. Hooper, D. C.; Wolfson, J. S.; McHugh, G. L.; Winters, M. B.; Swartz, M.N. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob. Agents Chemother. 1982, 22, 662-671.
56. Hickman, J. A. Apoptosis and tumourigenesis. Curr. Opin. Genet. Dev. 2002, 12, 67-72.
57. (a) Gagne, D.; Balaguer, P.; Demirpence, E.; Chabret, C.; Trousse, F.; Nicolas, J. C.; Pons, M. Stable luciferase transfected cells for studying steroid receptor biological activity. J. Biolumin. Chemilumin. 1994, 9, 201-209.
58. (b) Balaguer, P.; Francois, F.; Comunale, F.; Fenet, H.; Boussioux, A. M.; Pons, N.; Nicolas, J. C.; Casellas, C. Reporter cell lines to study the estrogenic effects of xenoestrogens. Sci. Total Environ. 1999, 233, 47-56.